Case Reports
Hexamethylene bisacetamide-induced cutaneous vasculitis
- PMID: 3567971
Item in Clipboard
Case Reports
Hexamethylene bisacetamide-induced cutaneous vasculitis
Cancer Treat Rep.
1987 May.
Abstract
Nonthrombocytopenic purpura developed in a patient receiving hexamethylene bisacetamide, a tumor-differentiating agent in vitro that is in phase I clinical trials. Histopathological examination revealed features of leukocytoclastic vasculitis with deposition of IgA and complement in the dermal vasculature. Leukocytoclastic vasculitis, an extremely rare complication of therapy with antineoplastic agents, is reported to alert others using this compound of this association.
Similar articles
-
Quinidine-induced vasculitis.Arch Intern Med. 1985 Nov;145(11):2051-2. Arch Intern Med. 1985. PMID: 4062457
-
Rituximab-induced leukocytoclastic vasculitis: a case report.Arch Dermatol. 2006 Feb;142(2):246-7. doi: 10.1001/archderm.142.2.246. Arch Dermatol. 2006. PMID: 16490860 No abstract available.
-
Circulating and tissue-bound immune complexes in allergic vasculitis: relationship between immunoglobulin class and clinical features.Clin Exp Immunol. 1980 Sep;41(3):459-70. Clin Exp Immunol. 1980. PMID: 7438561 Free PMC article.
-
Leukocytoclastic vasculitis associated with immunoglobulin A lambda monoclonal gammopathy of undetermined significance: A case report and review of previously reported cases.J Dermatol. 2018 Aug;45(8):1009-1012. doi: 10.1111/1346-8138.14466. Epub 2018 May 15. J Dermatol. 2018. PMID: 29766549 Review.
-
Immunologic aspects of cutaneous vasculitis.Semin Dermatol. 1988 Jun;7(2):140-8. Semin Dermatol. 1988. PMID: 3153435 Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous